Tirzepatide vs Semaglutide

Side-by-side comparison of Tirzepatide, Semaglutide — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss
Basics
Molecular type Dual GIP/GLP-1 Receptor AgonistGLP-1 Receptor Agonist
Amino acids 3931
Molecular weight 4,813.5 Da4,113.6 Da
Half-life ~5 days~7 days
Route(s) Subcutaneous injectionSubcutaneous injection, Oral (Rybelsus)
Mechanism & Research
Primary mechanism Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend…
Research status FDA Approved FDA Approved
Evidence summary Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici…
Protocol & Dosing
Typical dose 2.5mg → 15mg weekly0.25mg → 2.4mg weekly (weight management)
Frequency Once weeklyOnce weekly
Duration Ongoing (chronic)Ongoing (chronic management)
Timing Same day each week, any time of daySame day each week, any time
Safety
Common side effects
  • Nausea (33–40%)
  • Diarrhoea (17–22%)
  • Vomiting (11–13%)
  • Constipation (11–12%)
  • Nausea (44%)
  • Diarrhoea (30%)
  • Vomiting (24%)
  • Constipation (24%)
Contraindications
  • Personal/family history of MEN2 or medullary thyroid carcinoma
  • Known GIP or GLP-1 receptor agonist hypersensitivity
  • Severe renal impairment (caution)
  • Personal/family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pancreatitis history
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides Semaglutide, AOD-9604, Tesamorelin Tirzepatide, AOD-9604, Tesamorelin
Full profile Read full Tirzepatide profile → Read full Semaglutide profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.